权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Measurement of Retinal Nerves and Blood Vessels as Markers for Type 1 Diabetes

测量视网膜神经和血管作为 1 型糖尿病的标志物

基本信息

批准号：
9754819
负责人：
Mircea Mujat
金额：
$ 50.47万
依托单位：
PHYSICAL SCIENCES, INC
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9754819
关键词：
Affect Axon Biological Markers Blood Vessels Blood capillaries Boston Characteristics Clinic Clinical Clinical Engineering Clinical Management Collaborations Complex Complications of Diabetes Mellitus Data Detection Diabetes Mellitus Diabetic Retinopathy Diagnosis Diagnostic Disease Disease Marker Disease Progression Early Diagnosis Evolution Fiber Optics Funding Histopathology Human Volunteers Image Imagery Imaging Techniques Imaging technology Incidence Insulin-Dependent Diabetes Mellitus Knowledge Laboratory Research Lasers Light Market Research Measurement Medical Metabolic Modality Monitor Morphologic artifacts Morphology Nerve Nerve Fibers Neurons Ophthalmologist Ophthalmoscopy Optical Coherence Tomography Patients Pediatric Hospitals Pericytes Phase Photoreceptors Population Positioning Attribute Publications Recording of previous events Reperfusion Therapy Research Research Personnel Resolution Retina Retinal Scanning Scheme Structure System Techniques Technology Testing Tissues Traction Treatment Efficacy United States National Institutes of Health Vision Vision research adaptive optics adaptive optics scanning laser ophthalmoscopy base clinical Diagnosis clinical investigation commercialization design disease diagnosis early detection biomarkers fundamental research healthy volunteer high resolution imaging imager imaging approach imaging capabilities imaging modality imaging platform improved in vivo instrument multimodality neurovascular new technology next generation non-invasive imaging novel optical imaging physical science programs prototype retina blood vessel structure retinal imaging specific biomarkers tool treatment response volunteer

项目摘要

Project Summary/Abstract There is currently a significant need for new non-invasive imaging techniques able to accurately quantify biomarkers for early detection, diagnosis, and quantification of complications in type 1 diabetes (T1D) such as diabetic retinopathy (DR). Physical Sciences Inc. (PSI) proposes to develop an imaging platform based on a new detection arrangement retrofitted to an existing high-resolution retinal imaging platform that includes adaptive optics-assisted scanning laser ophthalmoscopy (AO-SLO) and Optical Coherence Tomography (OCT). The new technique will allow for visualization and quantification of blood vessels structure and nerve bundle arrangement with exquisite details afforded by AO. The proposed detection scheme will be first tested and demonstrated using an existing multimodal AO retinal imager (MAORI) in Phase I and then in Phase II a new MAORI prototype will be developed specifically for imaging particular characteristics of retinal alterations induces by diabetes. Specific biomarkers for T1D complications will be defined based on patient data acquired by our collaborators from Boston Children's Hospital. About 40 patients with different stages of DR will be imaged during the Phase II Program. PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for the ophthalmic research market. PSI and our collaborators have recognized that one of the main impediments in developing a clinical market for AO-SLO's is that there have been few in-depth studies on the medical application of AO imagers for disease diagnosis and tracking the efficacy of treatments. Despite a relatively large number of research publications on the benefits of AO on understanding fundamental aspects of vision, so far AO has not gained traction in the clinical market. However, given the large incidence of neurovascular diseases, it is possible that the proposed application to use high- resolution retinal imaging to investigate the retinal changes due to diabetes will generate significant drive to bring AO closer to the clinical market. Therefore, PSI is requesting funding for developing this technology with a potentially significant impact on vision research and subsequently on the clinical diagnosis and management of DR.

项目总结/文摘